Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study. (Q50561292)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 September 2010

Language	Label	Description	Also known as
English	Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study.	scientific article published on 10 September 2010

Statements

scholarly article

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study. (English)

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

5

object named as

Noriko Usui

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

author name string

Itsuro Jinnai

1

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Tohru Sakura

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Motohiro Tsuzuki

3

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Yasuhiro Maeda

4

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Masayuki Kato

6

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Hirokazu Okumura

7

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Taiichi Kyo

8

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Yasunori Ueda

9

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Yuji Kishimoto

10

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Fumiharu Yagasaki

11

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Kosuke Tsuboi

12

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Shigeo Horiike

13

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Jin Takeuchi

14

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Masako Iwanaga

15

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Yasushi Miyazaki

16

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Shuichi Miyawaki

17

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Kazunori Ohnishi

18

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Tomoki Naoe

19

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Ryuzo Ohno

20

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

publication date

10 September 2010

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

International Journal of Hematology

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

92

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

490-502

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

3

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

https://scigraph.springernature.com/pub.10.1007/s12185-010-0672-z

0 references

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A note on quantifying follow-up in studies of failure time

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival rates

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-010-0672-Z

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/20830614

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50561292&oldid=1826513065"